It is estimated that annually more than 6 million Americans suffer from unruptured cerebral aneurysms. Personnel of the neurovascular device company Galaxy note, however, that the data suggests that devices typically used to treat cerebral aneurysms have a unimpressive effective rate -- estimated at perhaps as low as 50%. To address these shortcomings, Galaxy Therapeutics personnel are tackling development of a treatment device that will address and tackle these shortcomings.
